Keros Therapeutics, Inc. (KROS)
NASDAQ
Market Cap
$1.64B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
631 of 809
Rank in Industry
343 of 445
Largest Insider Buys in Sector
KROS Stock Price History Chart
KROS Stock Performance
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Insider Activity of Keros Therapeutics, Inc.
Over the last 12 months, insiders at Keros Therapeutics, Inc. have bought $0 and sold $1.81M worth of Keros Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Keros Therapeutics, Inc. have bought $46.18M and sold $10.17M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 120,000 shares for transaction amount of $6M was made by Kariv Tomer () on 2020‑11‑17.
List of Insider Buy and Sell Transactions, Keros Therapeutics, Inc.
| 2023-11-04 | Sale | Regnante Keith | Chief Financial Officer | 40,000 0.1912% | $45.29 | $1.81M | +0.36% | |
| 2023-06-09 | Sale | Regnante Keith | Chief Financial Officer | 20,000 0.073% | $45.42 | $908,367 | -6.61% | |
| 2023-06-08 | Sale | Regnante Keith | Chief Financial Officer | 20,000 0.0688% | $47.79 | $955,872 | -16.16% | |
| 2022-07-15 | Sale | Lachey Jennifer | Chief Scientific Officer | 46,034 0.1768% | $30.00 | $1.38M | +44.95% | |
| 2022-07-13 | Sale | Lachey Jennifer | Chief Scientific Officer | 1,916 0.0075% | $30.00 | $57,480 | +48.06% | |
| 2022-05-11 | Sale | Lachey Jennifer | Chief Scientific Officer | 944 0.004% | $42.49 | $40,111 | +3.60% | |
| 2022-04-11 | Sale | Lachey Jennifer | Chief Scientific Officer | 559 0.0024% | $64.15 | $35,860 | -29.72% | |
| 2022-04-06 | Sale | Rovaldi Christopher | Chief Operating Officer | 1,728 0.007% | $65.00 | $112,320 | -33.79% | |
| 2022-04-04 | Sale | Lachey Jennifer | Chief Scientific Officer | 7,950 0.0315% | $60.00 | $477,000 | -30.15% | |
| 2022-04-01 | Sale | Rovaldi Christopher | Chief Operating Officer | 366 0.0015% | $57.97 | $21,217 | -25.78% | |
| 2022-03-11 | Sale | Lachey Jennifer | Chief Scientific Officer | 875 0.0038% | $54.54 | $47,723 | -11.26% | |
| 2022-02-11 | Sale | Lachey Jennifer | Chief Scientific Officer | 2,650 0.0112% | $52.06 | $137,965 | -10.70% | |
| 2022-01-11 | Sale | Lachey Jennifer | Chief Scientific Officer | 2,650 0.0109% | $53.75 | $142,447 | -16.23% | |
| 2022-01-05 | Sale | Knowles Julius | director | 4,034 0.0174% | $58.25 | $234,991 | -18.81% | |
| 2022-01-05 | Sale | Lachey Jennifer | Chief Scientific Officer | 2,650 0.0118% | $60.00 | $159,000 | -18.81% | |
| 2022-01-04 | Sale | Knowles Julius | director | 20,062 0.082% | $57.55 | $1.15M | -21.81% | |
| 2022-01-03 | Sale | Knowles Julius | director | 23,555 0.0959% | $58.01 | $1.37M | -22.56% | |
| 2021-12-15 | Sale | Lachey Jennifer | Chief Scientific Officer | 735 0.003% | $50.00 | $36,750 | -11.75% | |
| 2021-12-13 | Sale | Lachey Jennifer | Chief Scientific Officer | 1,915 0.0084% | $50.55 | $96,808 | -5.99% | |
| 2021-12-02 | Sale | Knowles Julius | director | 25,338 0.1068% | $53.57 | $1.36M | -14.99% |
Insider Historical Profitability
87.24%
| Regnante Keith | Chief Financial Officer | 0 0% | $45.55 | 0 | 3 | |
| Kariv Tomer | 2288151 6.8386% | $45.55 | 2 | 0 | +51.74% | |
| Nussbaum Ran | 2288151 6.8386% | $45.55 | 2 | 0 | +51.74% | |
| Pontifax Management 4 G.P. (2015) Ltd. | 10 percent owner | 2288151 6.8386% | $45.55 | 2 | 0 | +51.74% |
| Lazarus Alon | 2013102 6.0166% | $45.55 | 1 | 0 | +122.73% | |
| Arkin Bio Ventures Limited Partnership | 10 percent owner | 2013102 6.0166% | $45.55 | 1 | 0 | +122.73% |
| GORDON CARL L | director | 1119812 3.3468% | $45.55 | 1 | 0 | +122.73% |
| ORBIMED ADVISORS LLC | director | 1119812 3.3468% | $45.55 | 1 | 0 | +122.73% |
| Seehra Jasbir | Chief Executive Officer | 243856 0.7288% | $45.55 | 1 | 0 | +122.73% |
| Knowles Julius | director | 232727 0.6956% | $45.55 | 1 | 38 | +122.73% |
| Lachey Jennifer | Chief Scientific Officer | 95100 0.2842% | $45.55 | 0 | 19 | |
| Ordonez Claudia | Chief Medical Officer | 0 0% | $45.55 | 0 | 5 | |
| Rovaldi Christopher | Chief Operating Officer | 0 0% | $45.55 | 0 | 2 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Fidelity Investments | $332.23M | 13.91 | 5.02M | +29.54% | +$75.75M | 0.02 | |
| BlackRock | $143.39M | 6 | 2.17M | +6.34% | +$8.55M | <0.01 | |
| Alkeon Capital Management Llc | $105.85M | 4.43 | 1.6M | +6.67% | +$6.62M | 0.58 | |
| State Street | $103.46M | 4.33 | 1.56M | +48.23% | +$33.66M | <0.01 | |
| The Vanguard Group | $102.33M | 4.28 | 1.55M | +7.93% | +$7.52M | <0.01 | |
| Darwin Global Management Ltd | $95.06M | 3.98 | 1.44M | +35.41% | +$24.86M | 14.13 | |
| OrbiMed | $83.99M | 3.52 | 1.27M | 0% | +$0 | 1.72 | |
| T. Rowe Price | $80.67M | 3.38 | 1.22M | +16.97% | +$11.7M | 0.01 | |
| Point72 Asset Management | $64.34M | 2.69 | 971,881 | +1,096.46% | +$58.96M | 0.12 | |
| Tcg Crossover Management Llc | $58.21M | 2.44 | 879,344 | New | +$58.21M | 0.09 | |
| Woodline Partners LP | $50.42M | 2.11 | 761,700 | +30.48% | +$11.78M | 0.48 | |
| Braidwell Lp | $48.81M | 2.04 | 737,379 | -34.1% | -$25.26M | 2.75 | |
| Eventide Asset Management | $45.02M | 1.88 | 680,000 | +17.24% | +$6.62M | 0.71 | |
| Candriam S C A | $43.16M | 1.81 | 651,999 | -20.4% | -$11.06M | 0.28 | |
| Holocene Advisors, LP | $42.23M | 1.77 | 637,983 | New | +$42.23M | 0.16 | |
| Jefferies Financial Group | $41.95M | 1.76 | 633,671 | +3,885.35% | +$40.9M | 0.76 | |
| Franklin Templeton Investments | $41.84M | 1.75 | 632,049 | -9.63% | -$4.46M | 0.01 | |
| Geode Capital Management | $39.45M | 1.65 | 595,846 | +16.78% | +$5.67M | <0.01 | |
| Redmile Group | $36.58M | 1.53 | 552,506 | New | +$36.58M | 1.36 | |
| Citadel Advisors LLC | $29.81M | 1.25 | 450,278 | -40.77% | -$20.51M | 0.02 | |
| Opaleye Management Inc | $24.33M | 1.02 | 367,500 | +2.8% | +$662,000.00 | 3.84 | |
| Millennium Management LLC | $22.35M | 0.94 | 337,663 | -35.33% | -$12.21M | 0.02 | |
| Nantahala Capital Management Llc | $19.46M | 0.82 | 293,997 | -5.21% | -$1.07M | 2 | |
| Morgan Stanley | $19.14M | 0.8 | 289,157 | -68.75% | -$42.12M | <0.01 | |
| Soleus Capital Management, L.P. | $18.11M | 0.76 | 273,600 | New | +$18.11M | 0.17 | |
| Marshall Wace | $18.07M | 0.76 | 272,971 | +451.77% | +$14.8M | 0.02 | |
| Goldman Sachs | $17.1M | 0.72 | 258,368 | +25.97% | +$3.53M | <0.01 | |
| American Century Investments | $15.81M | 0.66 | 238,806 | +11.28% | +$1.6M | 0.01 | |
| Northern Trust | $15.6M | 0.65 | 235,638 | +8.67% | +$1.24M | <0.01 | |
| Avidity Partners Management Lp | $13.88M | 0.58 | 209,700 | New | +$13.88M | 0.5 | |
| Charles Schwab | $13.75M | 0.58 | 207,758 | +14.42% | +$1.73M | <0.01 | |
| Cibc World Markets Corp | $13.24M | 0.55 | 200,000 | New | +$13.24M | 0.09 | |
| Adage Capital Partners Gp L L C | $12.58M | 0.53 | 190,000 | New | +$12.58M | 0.02 | |
| Ecor1 Capital Llc | $12.41M | 0.52 | 187,500 | New | +$12.41M | 0.32 | |
| Parkman Healthcare Partners Llc | $11.81M | 0.49 | 178,335 | -50.53% | -$12.06M | 1.46 | |
| Bank of America | $11.42M | 0.48 | 172,477 | -10.84% | -$1.39M | <0.01 | |
| Blue Owl Capital Holdings Lp | $11.43M | 0.48 | 172,633 | -51.05% | -$11.92M | 2.15 | |
| Dimensional Fund Advisors | $10.95M | 0.46 | 165,406 | -3.19% | -$360,525.16 | <0.01 | |
| Granahan Investment Management | $9.86M | 0.41 | 149,013 | New | +$9.86M | 0.35 | |
| Deutsche Bank | $8.21M | 0.34 | 124,072 | -65.37% | -$15.5M | <0.01 | |
| UBS | $8.22M | 0.34 | 124,185 | -31.54% | -$3.79M | <0.01 | |
| Rafferty Asset Management Llc | $7.91M | 0.33 | 119,511 | +83.07% | +$3.59M | 0.02 | |
| Citigroup | $7.78M | 0.33 | 117,456 | -30.66% | -$3.44M | 0.01 | |
| WCM Investment Management | $7.75M | 0.32 | 117,030 | -24.33% | -$2.49M | 0.02 | |
| Nuveen | $6.7M | 0.28 | 101,239 | +33.92% | +$1.7M | <0.01 | |
| BNY Mellon | $6.6M | 0.28 | 99,633 | +5.43% | +$339,539.77 | <0.01 | |
| Readystate Asset Management Lp | $6.25M | 0.26 | 94,373 | New | +$6.25M | 0.35 | |
| AllianceBernstein | $6.08M | 0.26 | 91,858 | +334.93% | +$4.68M | <0.01 | |
| Invesco | $5.87M | 0.25 | 88,683 | +788.61% | +$5.21M | <0.01 | |
| Russell Investments Group Ltd | $5.45M | 0.23 | 82,352 | -12.91% | -$807,970.79 | 0.01 |